World Health Organization. World malaria report. 2018 [internet publication].
World Health Organization. Guidelines for the treatment of malaria: third edition. 2015 [internet publication].
Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Part 2: general approach to treatment and treatment of uncomplicated malaria. Apr 2019 [internet publication].
Ballard SB, Salinger A, Arguin PM, et al. Updated CDC recommendations for using artemether-lumefantrine for the treatment of uncomplicated malaria in pregnant women in the United States. MMWR Morb Mortal Wkly Rep. 2018 Apr 13;67(14):424-31.
1. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005 Mar 10;434(7030):214-7.
3. Evans RJ. Nosocomial malaria. Lancet. 1997 Feb 22;349(9051):574.
4. Moro ML, Romi R, Severini C, et al. Patient-to-patient transmission of nosocomial malaria in Italy. Infect Control Hosp Epidemiol. 2002 Jun;23(6):338-41.
5. Das D, Bhattacharjee K, Ghintala S, et al. Bilateral cervical lymphadenopathy atypical presentation of malaria - a rare case report. J Clin Diagn Res. 2017 Apr;11(4):OD08-OD09.
6. Groger M, Fischer HS, Veletzky L, et al. A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria. Malar J. 2017 Mar 11;16(1):112.
7. World Health Organization. World malaria report. 2018 [internet publication].
8. Mace KE, Arguin PM, Tan KR. Malaria surveillance - United States, 2015. MMWR Surveill Summ. 2018 May 4;67(7):1-28.
9. Public Health England. Malaria imported into the United Kingdom: 2017 – implications for those advising travellers. Jul 2018 [internet publication].
10. World Health Organization. Global technical strategy for malaria 2016-2030. Jun 2015 [internet publication].
11. Luxemburger C, Ricci F, Nosten F, et al. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62.
12. Wellems TE, Miller LH. Two worlds of malaria. N Engl J Med. 2003 Oct 16;349(16):1496-8.
13. Behrens RH, Carroll B, Smith V, et al. Declining incidence of malaria imported into the UK from West Africa. Malar J. 2008 Nov 10;7:235.
14. Mungai M, Tegtmeier G, Chamberland M, et al. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001 Jun 28;344(26):1973-8.
15. Centers for Disease Control and Prevention. Malaria outbreak: Bahia State, Brazil. Jan 2018 [internet publication].
16. Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG. 2005 Sep;112(9):1189-95.
17. Mendis K, Sina BJ, Marchesini P, et al. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):97-106.
18. Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev. 2005 Jul;18(3):570-81.
19. Boudin C, Robert V, Verhave JP, et al. Plasmodium falciparum and P. malariae epidemiology in a West African village. Bull World Health Organ. 1991;69(2):199-205.
20. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale - the "bashful" malaria parasites. Trends Parasitol. 2007 Jun;23(6):278-83.
21. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev. 2007 Oct;20(4):579-92.
22. Brasil P, Zalis MG, de Pina-Costa A, et al. Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation. Lancet Glob Health. 2017 Oct;5(10):e1038-46.
23. Lalloo DG, Shingadia D, Bell DJ, et al. UK malaria treatment guidelines 2016. J Infect. 2016 Jun;72(6):635-49.
24. Miller LH, Baruch DI, Marsh K, et al. The pathogenic basis of malaria. Nature. 2002 Feb 7;415(6872):673-9.
25. Behrens RH, Carroll B, Beran J, et al; TropNetEurop. The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis? Malar J. 2007 Aug 23;6:114.
26. Behrens RH, Bisoffi Z, Björkman A, et al; TropNetEurop. Malaria prophylaxis policy for travellers from Europe to the Indian sub-continent. Malar J. 2006 Feb 1;5:7.
27. Krause G, Schöneberg I, Altmann D, et al. Chemoprophylaxis and malaria death rates. Emerg Infect Dis. 2006 Mar;12(3):447-51.
28. Smith AD, Bradley DJ, Smith V, et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ. 2008 Jul 3;337:a120.
29. Brabin BJ, Romagosa C, Abdelgalil S, et al. The sick placenta - the role of malaria. Placenta. 2004 May;25(5):359-78.
30. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000 Apr;94(suppl 1):S1-90.
31. Greenberg AE, Lobel HO. Mortality from plasmodium falciparum malaria in travelers from the United States, 1959 to 1987. Ann Intern Med. 1990 Aug 15;113(4):326-7.
32. Moore DA, Jennings RM, Doherty TF, et al. Assessing the severity of malaria. BMJ. 2003 Apr 12;326(7393):808-9.
33. Hammerich A, Campbell OM, Chandramohan D. Unstable malaria transmission and maternal mortality - experiences from Rwanda. Trop Med Int Health. 2002 Jul;7(7):573-6.
34. Moya-Alvarez V, Bodeau-Livinec F, Cot M. Iron and malaria: a dangerous liaison? Nutr Rev. 2016 Oct;74(10):612-23.
35. Neuberger A, Okebe J, Yahav D, et al. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. 2016 Feb 27;(2):CD006589.
36. Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. Cochrane Database Syst Rev. 2018 Nov 6;(11):CD000363.
37. Tiono AB, Ouédraogo A, Ouattara D, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet. 2018 Aug 18;392(10147):569-80.
38. Gleave K, Lissenden N, Richardson M, et al. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev. 2018 Nov 29;(11):CD012776.
39. Maia MF, Kliner M, Richardson M, et al. Mosquito repellents for malaria prevention. Cochrane Database Syst Rev. 2018 Feb 6;(2):CD011595.
40. Fivelman QL, Butcher GA, Adagu IS, et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J. 2002 Feb 8;1:1.
41. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003 Aug 1;37(3):450-1.
42. Wichmann O, Muehlen M, Gruss H, et al. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J. 2004 Jun 8;3:14.
43. Tickell-Painter M, Maayan N, Saunders R, et al. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev. 2017 Oct 30;(10):CD006491.
44. Kolifarhood G, Raeisi A, Ranjbar M, et al. Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: a meta-analysis and systematic review. Travel Med Infect Dis. 2017 May - Jun;17:5-18.
45. Radeva-Petrova D, Kayentao K, ter Kuile FO, et al. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014 Oct 10;(10):CD000169.
46. González R, Pons-Duran C, Piqueras M, et al. Mefloquine for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2018 Nov 14;(11):CD011444.
47. Käser AK, Arguin PM, Chiodini PL, et al. Imported malaria in pregnant women: a retrospective pooled analysis. Travel Med Infect Dis. 2015 Jul-Aug;13(4):300-10.
48. Walshe DP, Garner P, Adeel AA, et al. Larvivorous fish for preventing malaria transmission. Cochrane Database Syst Rev. 2017 Dec 11;(12):CD008090.
49. Pryce J, Choi L, Richardson M, et al. Insecticide space spraying for preventing malaria transmission. Cochrane Database Syst Rev. 2018 Nov 2;(11):CD012689.
50. Hu KK, Maung C, Katz DL. Clinical diagnosis of malaria on the Thai-Myanmar border. Yale J Biol Med. 2001 Sep-Oct;74(5):303-8.
51. Payne D. Use and limitations of light microscopy for diagnosing malaria at the primary health care level. Bull World Health Organ. 1988;66(5):621-6.
52. Pattanasin S, Proux S, Chompasuk D, et al. Evaluation of a new Plasmodium lactate dehydrogenase assay (OptiMAL-IT) for the detection of malaria. Trans R Soc Trop Med Hyg. 2003 Nov-Dec;97(6):672-4.
53. Ashley E, Touabi M, Ahrer M, et al. Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria. Malar J. 2009 Oct 27;8:241.
54. Stauffer WM, Cartwright CP, Olson DA, et al. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis. 2009 Sep 15;49(6):908-13.
55. Nicastri E, Bevilacqua N, Sañé Schepisi M, et al. Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. Am J Trop Med Hyg. 2009 May;80(5):712-7.
56. Odaga J, Sinclair D, Lokong JA, et al. Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings. Cochrane Database Syst Rev. 2014 Apr 17;(4):CD008998.
57. World Health Organization. Guidelines for the treatment of malaria: third edition. 2015 [internet publication].
58. Li B, Sun Z, Li X, et al. Performance of pfHRP2 versus pLDH antigen rapid diagnostic tests for the detection of Plasmodium falciparum: a systematic review and meta-analysis. Arch Med Sci. 2017 Apr 1;13(3):541-9.
59. Hanscheid T. Diagnosis of malaria: a review of alternatives to conventional microscopy. Clin Lab Haematol. 1999 Aug;21(4):235-45.
60. Oliveira DA, Holloway BP, Durigon EL, et al. Polymerase chain reaction and a liquid-phase, nonisotopic hybridization for species-specific and sensitive detection of malaria infection. Am J Trop Med Hyg. 1995 Feb;52(2):139-44.
61. Rogerson SJ, Hviid L, Duffy PE,et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007 Feb;7(2):105-17.
62. Polley SD, González IJ, Mohamed D, et al. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. J Infect Dis. 2013 Aug 15;208(4):637-44.
63. Hopkins H, González IJ, Polley SD, et al. Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. J Infect Dis. 2013 Aug 15;208(4):645-52.
64. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4.
65. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20.
66. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204.
67. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.
68. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.
69. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.
70. World Health Organization. False-negative RDT results and implications of new reports of P. falciparum histidine-rich protein 2/3 gene deletions. May 2016 [internet publication].
71. Hanson J, Hossain A, Charunwatthana P, et al. Hyponatremia in severe malaria: evidence for an appropriate anti-diuretic hormone response to hypovolemia. Am J Trop Med Hyg. 2009 Jan;80(1):141-5.
72. Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev Anti Infect Ther. 2006 Dec;4(6):1039-49.
73. Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Part 2: general approach to treatment and treatment of uncomplicated malaria. Apr 2019 [internet publication].
74. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004 Jan 3;363(9402):9-17.
75. World Health Organization. Malaria: withdrawal of oral artemisinin-based monotherapies. Oct 2017 [internet publication].
76. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996 Jun 15;347(9016):1654-8.
77. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007483.
78. Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg. 2008 Feb;78(2):241-7.
79. Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011 May;17(5):771-7.
80. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012 Mar 31;11:102.
81. Rolling T, Schmiedel S, Wichmann D, et al. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J. 2012 May 17;11:169.
82. Askling HH, Bruneel F, Burchard G, et al. Management of imported malaria in Europe. Malar J. 2012 Sep 17;11:328.
83. D'Acremont V, Landry P, Mueller I, et al. Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg. 2002 May;66(5):481-6.
84. Melzer M, Lacey S, Rait G. The case for outpatient treatment of Plasmodium falciparum malaria in a selected UK immigrant population. J Infect. 2009 Oct;59(4):259-63.
85. Toovey S. Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria. Travel Med Infect Dis. 2008 Jan-Mar;6(1-2):29-31.
86. Briand V, Bouchaud O, Tourret J, et al. Hospitalization criteria in imported falciparum malaria. J Travel Med. 2007 Sep-Oct;14(5):306-11.
87. US Food and Drug Administration. Mefloquine hydrochloride: drug safety communication - FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. Jul 2013 [internet publication].
88. Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014 Jan 20;(1):CD010927.
89. Sondén K, Wyss K, Jovel I, et al. High rate of treatment failures in nonimmune travelers treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Sweden: retrospective comparative analysis of effectiveness and case series. Clin Infect Dis. 2017 Jan 15;64(2):199-206.
90. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016 Mar;16(3):357-65.
91. Chan XHS, Win YN, Mawer LJ, et al. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018 Aug;18(8):913-23.
92. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014 Nov 3;13:418.
93. Graves PM, Choi L, Gelband H, et al. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2018 Feb 2;(2):CD008152.
94. World Health Organization. Rectal artesunate for pre-referral treatment of severe malaria. Oct 2017 [internet publication].
95. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis. 2008 Jan 15;46(2):165-71.
96. Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated plasmodium falciparum and P vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003 Apr;68(4):416-20.
97. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012 Aug 17;11:280.
98. Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389.
99. World Health Organization. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale. Oct 2016 [internet publication].
100. Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15.
101. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):93-104.
102. Moore KA, Simpson JA, Scoullar MJL, et al. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017 Nov;5(11):e1101-12.
103. Cates JE, Unger HW, Briand V, et al. Malaria, malnutrition, and birthweight: a meta-analysis using individual participant data. PLoS Med. 2017 Aug 8;14(8):e1002373.
104. Newman RD, Parise ME, Slutsker L, et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health. 2003 Jun;8(6):488-506.
105. Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). Part 3: alternatives for pregnant women and treatment of severe malaria. Apr 2019 [internet publication].
106. Ballard SB, Salinger A, Arguin PM, et al. Updated CDC recommendations for using artemether-lumefantrine for the treatment of uncomplicated malaria in pregnant women in the United States. MMWR Morb Mortal Wkly Rep. 2018 Apr 13;67(14):424-31.
107. Kovacs SD, van Eijk AM, Sevene E, et al. The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis. PLoS One. 2016 Nov 8;11(11):e0164963.
108. Pekyi D, Ampromfi AA, Tinto H, et al; PREGACT Study Group. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016 Mar 10;374(10):913-27.
109. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016 Mar 10;374(10):928-39.
110. Desai M, Gutman J, L'Ianziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015 Dec 19;386(10012):2507-19.
111. Burger RJ, van Eijk AM, Bussink M, et al. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2015 Nov 12;3(1):ofv170.
112. Mavoko HM, Nabasumba C, da Luz RI, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health. 2017 Jan;5(1):e60-8.
113. Gil JP, Krishna S. pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. Expert Rev Anti Infect Ther. 2017 Jun;15(6):527-43.
114. World Health Organization. Status report on artemisinin and ACT resistance. Apr 2017 [internet publication].
115. Imwong M, Hien TT, Thuy-Nhien NT, et al. Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis. 2017 Oct;17(10):1022-3.
116. Maitland K, Kiguli S, Opoka RO, et al; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30;364(26):2483-95.
117. Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1025-34.
118. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019 Jan 17;380(3):215-28.
119. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019 Jan 17;380(3):229-41.
120. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018 Apr 7;391(10128):1378-90.
121. Pryce J, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2019 Jan 8;(1):CD006404.
122. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Jul 4;386(9988):31-45.
123. World Health Organization Regional Office for Africa. News: Ghana, Kenya and Malawi to take part in WHO malaria vaccine pilot programme. Apr 2017 [internet publication].
124. Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017 May;17(5):498-509.
125. Ishizuka AS, Lyke KE, DeZure A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 Jun;22(6):614-23.
126. Sulyok M, Rückle T, Roth A, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017 Jun;17(6):636-44.
127. McCarthy JS, Lotharius J, Rückle T, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis. 2017 Jun;17(6):626-35.
128. Deye GA, Miller RS, Miller L, et al. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. Clin Infect Dis. 2012 Jan 15;54(2):232-9.
129. Leshem E, Meltzer E, Stienlauf S, et al. Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa. J Travel Med. 2014 Mar-Apr;21(2):82-5.
130. Winters RA, Murray HW. Malaria - the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med. 1992 Sep;93(3):243-6.
131. Behrens RH, Curtis CF. Malaria in travellers: epidemiology and prevention. Br Med Bull. 1993 Apr;49(2):363-81.
132. White NJ. Not much progress in the treatment of cerebral malaria. Lancet. 1998 Aug 22;352(9128):594-5.
133. Bruneel F, Tubach F, Corne P, et al. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One. 2010 Oct 8;5(10):e13236.
134. Checkley AM, Smith A, Smith V, et al. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012 Mar 27;344:e2116.
135. Sypniewska P, Duda JF, Locatelli I, et al. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med. 2017 Aug 3;15(1):147.
136. English M, Waruiru C, Amukoye E, et al. Deep breathing in children with severe malaria: indicador of metabolic acidosis and poor outcome. Am J Trop Med Hyg. 1996 Nov;55(5):521-4.
137. Lon C, Spring M, Sok S, et al. Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine. Malar J. 2014 Mar 14;13:96.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台